HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hirst, C. E. Articles by Bird, P. I. Search for Related Content PubMed PubMed Citation Articles by Hirst, C. E. Articles by Bird, P. I.

The Intracellular Granzyme B Inhibitor, Proteinase Inhibitor 9, Is Up-Regulated During Accessory Cell Maturation and Effector Cell Degranulation, and Its Overexpression Enhances CTL Potency¹

Claire E. Hirst^*, Marguerite S. Buzza^*, Catherina H. Bird^*, Hilary S. Warren, Paul U. Cameron, Manling Zhang, Philip G. Ashton-Rickardt and Phillip I. Bird^2,*

^* Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia; Division of Immunology and Cell Biology, John Curtin School of Medical Research, Australian National University, Canberra City, Australia; Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia; and Department of Pathology, Ben May Institute for Cancer Research and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL 60637

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Granzyme B (grB) is a serine proteinase released by cytotoxic lymphocytes (CLs) to kill abnormal cells. GrB-mediated apoptotic pathways are conserved in nucleated cells; hence, CLs require mechanisms to protect against ectopic or misdirected grB. The nucleocytoplasmic serpin, proteinase inhibitor 9 (PI-9), is a potent inhibitor of grB that protects cells from grB-mediated apoptosis in model systems. Here we show that PI-9 is present in CD4⁺ cells, CD8⁺ T cells, NK cells, and at lower levels in B cells and myeloid cells. PI-9 is up-regulated in response to grB production and degranulation, and associates with grB-containing granules in activated CTLs and NK cells. Intracellular complexes of PI-9 and grB are evident in NK cells, and overexpression of PI-9 enhances CTL potency, suggesting that cytoplasmic grB, which may threaten CL viability, is rapidly inactivated by PI-9. Because dendritic cells (DCs) acquire characteristics similar to those of target cells to activate naive CD8⁺ T cells and therefore may also require protection against grB, we investigated the expression of PI-9 in DCs. PI-9 is evident in thymic DCs (CD3^-, CD4⁺, CD8^-, CD45⁺), tonsillar DCs, and DC subsets purified from peripheral blood (CD16⁺ monocytes and CD123⁺ plasmacytoid DCs). Furthermore, PI-9 is expressed in monocyte-derived DCs and is up-regulated upon TNF--induced maturation of monocyte-derived DCs. In conclusion, the presence and subcellular localization of PI-9 in leukocytes and DCs are consistent with a protective role against ectopic or misdirected grB during an immune response.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Natural killer cells and CTLs kill virus-infected and tumor cells by inducing apoptosis through exocytosis of cytotoxic granule contents or ligation of death receptors (reviewed in Ref. 1). Granzyme B (grB)³ is a key cytotoxic granule proteinase that is endocytosed by the target cell following cytotoxic lymphocyte (CL) degranulation, probably by binding to the mannose-6-phosphate receptor (M6PR) (2). The cytotoxic pore-forming protein, perforin, is also internalized and mediates the release of grB into the cytoplasm of the target cell. GrB then rapidly induces apoptosis by cleaving one or more cytoplasmic or nuclear proteins. These include Bid (3, 4, 5, 6), caspases (7, 8), components of the DNA repair machinery (7, 9), and inhibitor of caspase-activated DNase (10, 11).

Although CL granule contents are efficiently directed into the target cell via the immunological synapse (12), some grB may escape from granules or the synaptic zone into the cytoplasm of the CL or into the extracellular milieu. For example, free grB is evident in the sera of patients with elevated CTL responses (13) or severe Gram-negative bacterial infections (14). Given its cytotoxic potency and ability to degrade extracellular proteins (13, 15, 16, 17, 18), it is likely that protective mechanisms exist to counter misdirected or ectopic grB.

GrB is efficiently inhibited by the nucleocytoplasmic serpin, proteinase inhibitor 9 (PI-9) (19, 20), with transfection studies demonstrating that PI-9 protects cells from grB-mediated apoptosis (21). PI-9 is present in cells at immune-privileged sites such as testis and placenta (22, 23), and the expression of PI-9 in endothelial and mesothelial cells suggests that it protects bystander cells from grB released during an immune response (24). Here we show that PI-9 is up-regulated in CTLs in response to grB production and degranulation, that it associates with grB-containing granules in activated CTLs and NK cells, and that overexpression increases CTL potency. We also show that PI-9 is present in several dendritic cell (DC) types. The localization and regulated expression of PI-9 in these leukocyte subsets strongly support the hypothesis that PI-9 protects effector, accessory, and bystander cells from ectopic grB during an immune response.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Antibodies

PI-9 was detected with the specific mAb 7D8 (22) or with rabbit 12 or rabbit 15 polyclonal antisera raised against recombinant PI-9 (19). PI-6 was detected with mAb 3A (25). GrB was detected with 2C5 (26) or rabbit anti-grB/grH polyclonal antiserum (27), both provided by J. Trapani (The Peter MacCallum Cancer Institute, East Melbourne, Australia), or GrB-7 (Chemicon, Temecula, CA). CD markers were detected with hybridoma supernatants from 3C10 (CD14; provided by R. Steinmann, Rockefeller Institute, New York), FMC63 (CD19; provided by H. Zola, Child Health Research Institute, Adelaide, Australia), and OKT3 (CD3) and OKT8 (CD8; both from American Type Culture Collection (Manassas, VA). Anti-CD4 and anti-CD56 were obtained from BD Biosciences (Franklin Lakes, NJ). Actin was detected with anti-actin (I-19) from Santa Cruz Biotechnology (Santa Cruz, CA).

Intracellular flow cytometry

Intracellular flow cytometry was performed using peripheral blood drawn from healthy volunteers. Erythrocytes were removed from whole blood by lysis in 167 mM NH₄Cl, 10 mM KHCO₃, and 0.1 mM EDTA for 5 min at room temperature, centrifugation at 100 x g for 5 min, then washing twice in PBS containing 1% FCS and 0.02% sodium azide (repeated for all subsequent washes). Approximately 2.5 x 10⁶ PBLs were fixed in 4% formaldehyde in PBS for 10 min at room temperature, centrifuged, resuspended in FACS Permeabilizing Solution (BD Biosciences) for 10 min, centrifuged, washed, and incubated with 7D8 or isotype control Ab (IgG1; BD Biosciences) for 30 min. Cells were washed twice, then incubated with FITC-conjugated anti-mouse Ig (Chemicon). After two more washes the cells were analyzed using a FACSCalibur and CellQuest software (BD Biosciences).

Localization of ov-serpins in peripheral blood leukocytes

Highly purified B, CD4⁺, CD8⁺, monocyte, and NK cell populations were obtained from whole blood using RosetteSep Enrichment cocktails (StemCell Technologies, Vancouver, Canada) according to the manufacturer’s instructions. Cells were plated on poly-L-lysine-coated slides, fixed in 4% formaldehyde for 20 min, then permeabilized in 0.5% Triton X-100 for 5 min. PI-9 and PI-6 were detected with 7D8 hybridoma supernatant or 3A hybridoma supernatant, respectively. Bound Ab was detected with anti-mouse Ig conjugated to FITC. Cells were counterstained with propidium iodide (1 µg/ml), and cross-sections through the nucleus were obtained using laser scanning confocal microscopy (TCS-NT; Leica, Wetzlar, Germany). The purity of each cell population and the presence of any contaminating cell types were assessed using Abs to CD3, CD4, CD8, CD14, CD19, and CD56.

Retroviral transduction of human CTLs

A cDNA encoding PI-9 (19) was subcloned into the MIGR1 retroviral vector in the forward or reverse orientation. PI-9 mRNA was transcribed as a bicistronic message with green fluorescence protein (GFP) (28). Viral supernatant for transduction was obtained by transient transfection of the 293GP packaging cell line (29) using Lipofectamine Plus (Invitrogen, Carlsbad, CA). Supernatant was tested for transduction efficiency on Jurkat cells. PBLs were obtained from normal healthy donors and were cultured in for 2 days with PHA and human IL-2 (300 U/ml), then transduced with retrovirus (29). After transduction, PBLs underwent one round of rapid expansion with irradiated feeder cells (BRT Laboratories, Baltimore, MD), and the brightest GFP-expressing PBLs were purified by FACS. Sorted PBLs (72% GFP⁺, 75–80% CD8⁺) were then kept in culture by rapid expansion every 3 days. PI-9 mRNA was quantitated by real-time PCR on cDNA (30) using primers and probes specific for PI-9 and GAPDH, respectively (MegaBases, Evanston, IL). Retrovirally transduced PBLs were analyzed in ⁵¹Cr release assays (in triplicate wells) with hybridoma targets that express the anti-human CD3 mAb OKT3 (31). The percent specific lysis of JY cells, a human B lymphoblastoid cell line, was determined in parallel (<6% specific lysis) and subtracted from the lysis of the OKT3 hybridoma to report CTL killing only.

Expression of PI-9 in stimulated cytotoxic lymphocytes

YT cells (32) were cultured as previously described (20). PBMCs were isolated from whole blood using Ficoll-Paque Plus. PBMCs (depleted of monocytes by adherence to plastic) were cultured in IL-2 (Sigma-Aldrich, St. Louis, MO) or a combination of Con A and PMA (both from Sigma-Aldrich) as previously described (33). Culture-generated quiescent NK cells were cultured and activated as described previously (34, 35). At the indicated time points, activated cells were harvested, and cell lysates were prepared by lysis in Nonidet P-40 (NP40) lysis buffer (1% NP-40 in 50 mM Tris-HCl (pH 8.0), and 10 mM EDTA (pH 8.0)). To prevent postlysis association of PI-9 and grB, cells were lysed on ice in the presence of protease inhibitors (1 mM PMSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin, and 1 µg/ml pepstatin). Lysates from 0.5 x 10⁶ cells were resolved by reducing 12.5% SDS-PAGE, transferred to nitrocellulose, immunoblotted for PI-9 with 7D8, and detected with HRP-conjugated anti-mouse Ig (Chemicon) using ECL (NEN, PerkinElmer, Boston, MA). The membranes were stripped (62.5 mM Tris-HCl (pH 6.8), 2% SDS, and 0.1 M 2-ME for 30 min at 50°C), then reprobed for grB (2C5) and actin (diluted 1/1000). Densitometric analysis of PI-9 levels was determined using MCID Image Analysis software (BD Biosciences).

Formation of PI-9/grB complexes

Lysate from COS-1 cells transfected with PI-9 (20) was incubated with or without 100 ng of recombinant grB (36) at 37°C for 10 min. Samples were resolved by reducing 12.5% SDS-PAGE, transferred to nitrocellulose, and immunoblotted with rabbit 12 and rabbit 15 antisera (PI-9) or 2C5 (grB). YT cells (1 x 10⁶) were cultured for 20 h with or without 25 µM calpain inhibitor I (N-acetyl-Leu-Leu-Norleu; Sigma-Aldrich). Cells were lysed in NP-40 lysis buffer or modified Laemmli sample buffer (60 mM Tris-HCl (pH 6.8), 2% SDS, and 10% glycerol) (37) and passed through a 26-gauge needle to shear the DNA. Twenty micrograms of cell lysate was resolved by reducing 12.5% SDS-PAGE, transferred to nitrocellulose, immunoblotted with rabbit 12 antiserum, then stripped and reprobed with rabbit 15 antiserum.

Colocalization of PI-9 and grB

Activated CTLs were attached to poly-L-lysine-treated slides, fixed and permeabilized in 1/1 acetone/methanol for 2 min at room temperature, and stained for PI-9 (7D8), grB (rabbit anti-grB antiserum, diluted 1/200), or cathepsin A (rabbit antiserum, diluted 1/500, obtained from A. Pshezhetsky, University of Montreal, Montreal, Canada). Activated NK cells were cultured on irradiated MM-170 cells for 4 h, fixed in 4% formaldehyde, then permeabilized in 100% methanol and stained for PI-9 (7D8) and grB (rabbit anti-grB antiserum, diluted 1/200). YT cells were attached to poly-L-lysine-treated slides, fixed and permeabilized in acetone/methanol, and stained for PI-9 (rabbit anti-PI-9 antiserum, diluted 1/2000) and grB (2C5, diluted 1/200). BeWo cells were cultured and handled for microscopy as previously described (20). Primary Abs were detected with the appropriate secondary Ab conjugated to FITC or rhodamine B isothiocyanate (Chemicon). Two-color images were obtained using laser scanning confocal microscopy.

Tissue localization of PI-9

Human tissues fixed in neutral buffered formalin were obtained from the archive of the Pathology Department of Box Hill Hospital (Melbourne, Australia). Immunohistochemistry was performed as previously described (22). Cryopreserved normal human thymus was provided by R. Boyd (Department of Pathology and Immunology, Monash University, Prahran, Australia). Sections (6 µm) of tissue were air-dried onto silanized slides. Sections were washed and blocked in normal goat serum before incubation with 7D8 or an isotype-matched control Ab (IgG1). Bound Ab was detected with anti-mouse Ig conjugated to FITC. Sections were then stained with anti-CD3, -CD4, or -CD45 mAbs directly conjugated to PE (Diatec, Oslo, Norway). Two-color images were obtained using laser scanning confocal microscopy.

Dendritic cell purification

PBMCs were isolated from normal donors over Ficoll-Paque gradients (Red Cross Blood Transfusion Service, Melbourne, Australia). Monocytes were prepared by elutriation at 2100 rpm using a Beckman J6 M (Palo Alto, CA) with a standard chamber. Monocytes were further purified by sorting using a MoFlo CLS cell sorter (Cytomation, Fort Collins, CO) based on forward and side light scatter and subpopulations sorting for CD16⁺ and CD14⁺ expression. Lineage-negative DCs were purified from the monocyte elutriation fractions by negative selection with Abs to CD3, CD14, CD11b, CD19, and CD16. Lineage-negative DCs were sorted into CD1b/c⁺ (B-B5; BioSource International, Camarillo, CA) Langerhans cell precursors (38) or CD123⁺ (CD123, BD Bioscience) plasmacytoid DCs (39). MDDCs were generated from CD14⁺ monocytes positively selected using MACS columns after labeling for CD14 and goat anti-mouse MACS beads (Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were selected on a MACS column as recommended by the manufacturers. CD14⁺ monocytes were cultured in IL-4 (20 ng/ml) and GM-CSF (40 ng/ml) for 5–7 days as previously described (40). Immature DCs were matured in the presence of TNF- (10 ng/ml; R&D Systems, Minneapolis, MN) for 2 days.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Distribution of PI-9 in peripheral blood leukocytes

To extend our previous observations that PI-9 is expressed in lymphoid (T, B, and NK-like) cell lines, but not myeloid cell lines (19), we examined PI-9 in PBLs by intracellular flow cytometry using a specific mAb (22). PI-9 was evident in the majority of PBLs in both mononuclear cells (R1) and granulocytes (R2; Fig. 1A). Most mononuclear cells were clearly positive (>90%). Dual-color analysis showed that >95% of CD3⁺ cells are PI-9 positive, 100% of CD4⁺ and CD8⁺ cells are PI-9 positive, and 75% of CD19⁺ cells are PI-9 positive (data not shown). Many granulocytes (>70%) were also positive, but appeared to have lower amounts of PI-9, with only a slight positive shift in staining apparent over the isotype control (Fig. 1A). Comparison of the mean fluorescence intensities indicated that mononuclear cells express at least 5-fold more PI-9 than granulocytes.

View larger version (38K): [in this window] [in a new window]   FIGURE 1. Distribution of PI-9 in peripheral blood leukocytes. A, Flow cytometric analysis of PI-9 in PBLs. PBLs were stained with a PI-9-specific mAb, 7D8 (filled histogram), compared with an IgG1 isotype control (open histogram). This figure is representative of four different donors. B, Distribution and subcellular localization of PI-9 in PBL subsets. Leukocyte subsets were enriched and assessed as described in Materials and Methods. Indirect immunofluorescence was performed with a mAb specific to PI-9 (7D8) or PI-6 (3A) and was detected with FITC-conjugated anti-mouse Ig (green). The nuclei were counterstained with propidium iodide (red), and images were obtained using laser scanning confocal microscopy. Relative levels of PI-9 can be compared as all images were captured using the same settings. This figure is representative of three separate experiments. C, Proportion of PI-9- and PI-6-positive cells in enriched leukocyte subsets. Subsets were assessed for marker expression as described in Materials and Methods.

Intracellular localization of PI-9 in grB-expressing cells

The observation of high PI-9 expression in NK and CTLs suggests that it protects grB-producing cells against endogenous grB. Using indirect immunofluorescence and laser scanning confocal microscopy we examined the intracellular localization of PI-9 in primary NK cells and the NK-like cell line, YT. This showed that in addition to its previously reported cytoplasmic and nuclear distribution (Fig. 2A) (20), PI-9 is associated with vesicles in the CL cytoplasm that also contain grB (Fig. 2, B and C). These vesicles were positive for the lysosomal/granule marker lysosome-associated membrane protein-1 and not with markers for the endoplasmic reticulum or Golgi apparatus (data not shown), indicating that they are secretory lysosomes (cytotoxic granules). To determine whether the association of PI-9 with lysosomes is unique to CLs, the distribution of endogenous PI-9 in the epithelial cell line BeWo was also examined (Fig. 2D). Here PI-9 was evident only in the cytoplasm and nucleus, and no colocalization between PI-9 and lysosomal markers was observed.

View larger version (65K): [in this window] [in a new window]   FIGURE 2. Colocalization of PI-9 and grB in CLs. Activated CTLs (A) were stained for PI-9 (green), and the nucleus was counterstained with propidium iodide (PI; red). Activated NK cells on targets (B) or YT cells (C) were stained for PI-9 (green) and grB (red). Two-color images were obtained using laser scanning confocal microscopy. A and B, Single sections through the cell; C, a projected view of multiple scans through the depth of the cell at 1-µm intervals to give a three-dimensional representation of the entire cell; D, representative single sections of BeWo cells (choriocarcinoma) stained for PI-9 (green) and the lysosomal marker cathepsin A (red). No PI-9 association with lysosomes was evident in any of the cells inspected (n = 15; sampling all 0.3-µm sections generated through each cell).

View larger version (66K): [in this window] [in a new window]   FIGURE 3. Detection of preformed complexes in CLs. A, Rabbit anti PI-9 polyclonal antisera preferentially recognize complexes of PI-9 and grB as well as complex degradation products. Lysates of COS cells expressing PI-9 were incubated in the presence (+) or the absence (-) of excess grB, and samples were detected by immunoblotting with rabbit anti-PI-9 antisera R12 or R15, or the anti-grB mAb 2C5. Note that the 2C5 blot was overexposed to demonstrate that the Ab can detect grB in complex. B, Detection of preformed complexes in cytolytic cells. YT cells were incubated in the presence (+) or the absence (-) of a proteosome inhibitor (Prot. Inhib.), then lysed in NP40 or SDS lysis buffer. Cell lysates were immunoblotted with rabbit 15 antiserum, then stripped and reprobed with rabbit 12 antiserum. The position of uncomplexed PI-9 is arrowed, and the positions of the complex and primary degradation products are bracketed. Minor complex degradation products (*) are indicated on the right.

Because serpin/proteinase complexes are irreversible and involve distortion of both serpin and proteinase (42, 43), we predicted that cytoplasmic PI-9/grB complexes would be recognized and degraded by the ubiquitin-proteosomal machinery. Cells cultured in the presence of a proteosome inhibitor should therefore accumulate complexes. Indeed, greater amounts of complexes were detected by both PI-9 antisera when cells were incubated with the proteosomal inhibitor, calpain inhibitor I, and lysed in SDS (Fig. 3B). This also supports the idea that grB enters the cytoplasm of CLs during normal cellular function and is rapidly inactivated by PI-9.

PI-9 enhances the potency of human CTLs

Since PI-9 potentially protects CLs from death induced by misdirected grB, we wanted to determine the effect on CTL potency of overexpressing PI-9 in activated PBLs. Normal donor PBLs were activated with PHA and transduced with retroviral vectors containing the PI-9 gene in either the forward (coding) or the reverse (noncoding) orientation. These vectors allow transcription of the inserted cDNA as a bicistronic mRNA that also encodes GFP (28, 44). Cultures transduced with either the coding or noncoding vectors were enriched to equivalent amounts of GFP-expressing cells (72%) by FACS (data not shown). Those transduced with the PI-9 gene in the coding orientation expressed 4-fold higher levels of PI-9 mRNA (p < 0.02) compared with those in which the PI-9 gene was in the noncoding orientation (Fig. 4A). Both cultures contained an equal proportion of CD8 cells, which was 75–80% of the total PBLs (data not shown).

View larger version (13K): [in this window] [in a new window]   FIGURE 4. PI-9 enhances the potency of human CTLs. PBLs were transduced with bicistronic retroviral vectors containing a PI-9 cDNA in the forward (coding) or reverse (noncoding) direction in a transcriptional unit also encoding GFP. A, Relative levels of PI-9 mRNA in GFP-positive PBLs. Results are expressed as the concentration of PI-9 mRNA/the concentration of GAPDH mRNA, and are the mean ± SEM of four determinations from two separate experiments. Cells transduced with PI-9-coding virus expressed more PI-9 mRNA than those transduced with noncoding virus (**, p < 0.02). B, Specific CTL lysis by PBLs after transduction with retrovirus. These values represent the specific lysis of OKT3 targets minus the lysis of JY targets (<6%) and thus reflect killing by TCR-positive CTLs. Results are the mean ± SEM of four wells. CTLs that overexpressed coding PI-9 mRNA gave greater percent specific lysis than CTLs transduced with noncoding control virus (**, p < 0.02; *, p < 0.05). Similar results were found in two separate experiments.

Regulation of PI-9 in grB-expressing cells

CL stimulation, which increases the level of grB, should also result in a corresponding increase in PI-9. We therefore examined the regulation of PI-9 in T and NK cells under conditions known to induce grB synthesis and release. PBLs were stimulated with IL-2, which expands and activates T cells, or a combination of Con A and PMA, which results in T cell activation and granule exocytosis. As shown by immunoblotting, both these stimuli induced grB expression, peaking on days 6 and 3, respectively (Fig. 5, A and B). No significant increase in PI-9 was observed in T cells stimulated with IL-2 alone (Fig. 5A). However, stimulation of T cells with Con A/PMA resulted in a 3-fold induction of PI-9 over endogenous levels (Fig. 5B). This treatment also generated the higher M_r form of grB (35 kDa) that is only observed following T cell degranulation (45). Thus, in vitro, PI-9 up-regulation is associated with the release of grB from CLs.

View larger version (29K): [in this window] [in a new window]   FIGURE 5. Regulation of PI-9 expression in CLs. PBMCs were activated in the presence of 100 U/ml IL-2 (A) or a combination of Con A and PMA (10 µg/ml and 10 ng/ml, respectively; B), or culture-generated quiescent NK cells (C) were activated in the presence of irradiated MM-170 cells and 200 U/ml IL-2. On the indicated days cells were harvested, and lysates were prepared. Cells (0.5 x 106) loaded/lane) were resolved by reducing SDS-PAGE and sequentially immunoblotted with mAbs to PI-9 (7D8, hybridoma supernatant diluted 1/10), grB (2C5, diluted 1/2000), and an antiserum to actin (diluted 1/1000). FACS analysis indicated that 40% of IL-2-stimulated T cells and 64% of Con A/PMA-stimulated T cells were CD8+. *, Presence of the 35-kDa form of grB. Densitometric analysis was performed on immunoblots from four separate stimulations, and the relative levels of PI-9 are plotted.

Since PI-9 is up-regulated in response to T cell degranulation in vitro, its expression was also investigated in activated T cells in vivo by immunohistochemical analysis of normal and inflamed human tissues. When normal spleen was examined using the specific PI-9 mAb, 7D8, in standard immunohistochemical procedures, no PI-9-positive lymphocytes were detected (Fig. 6, b and c). However, when lymphocytes were extracted from freshly isolated spleen and stained for PI-9 using the more sensitive technique of indirect immunofluorescence, PI-9-positive cells were apparent (Fig. 6a). This indicated that the level of PI-9 expressed in quiescent lymphocytes is below the level of immunohistochemical detection using this Ab. By contrast, when we examined inflamed tissue samples by immunohistochemistry, PI-9-positive cells were clearly evident within lymphocytic infiltrates. For example, PI-9-positive lymphocytes were observed in sections of a ductal carcinoma of the breast (Fig. 6d) that were also positive for grB (Fig. 6e). Thus, PI-9 is up-regulated in grB-expressing effector cells in vivo.

View larger version (125K): [in this window] [in a new window]   FIGURE 6. Expression of PI-9 in activated lymphocytes and DCs. a, Indirect immunofluorescence of PI-9 (green) in lymphocytes isolated from normal spleen; b, PI-9 is undetectable by immunohistochemistry in formalin-fixed, paraffin-embedded normal spleen; c, isotype control of a serial section of the same normal spleen; d, PI-9 in activated lymphocytes in ductal breast carcinoma; e, coexpression of grB in activated lymphocytes; f, isotype control; g, localization of PI-9 to DCs within a tonsillar germinal center; h, higher magnification illustrating the dendritic morphology of the PI-9-positive cells; i, isotype control; j–l, PI-9-positive cells within the thymus. PI-9-positive cells (green) are located within the medulla identified by the presence of Hassall corpuscles (HC). PI-9 does not colocalize with CD3+ thymocytes (j, red), but slight colocalization is noted where cytosolic PI-9 overlaps with membrane CD45 (k, red) and CD4 (l, red) expressed on DCs.

In addition to protecting CLs from endogenous grB, PI-9 should protect accessory and bystander cells from exogenous grB released during the immune response. Supporting this idea, PI-9-positive DCs were evident in tonsillar germinal centers using the immunohistochemical procedures described above (Fig. 6, g and h). PI-9-positive DCs were also detected by two-color immunofluorescence in the thymus. These thymic PI-9-positive cells were CD3^- CD4⁺ CD45⁺ (Fig. 6, j–l) and CD8^- (data not shown) with DC morphology and were located in the keratin-negative medulla. The morphology and phenotype of these PI-9-positive DCs are consistent with several populations of human thymic DCs recently described (46). It is important to note that no PI-9-positive lymphocytes were detected in either tonsil or thymus, suggesting that DCs constitutively express higher levels of PI-9 compared with resting or immature lymphocytes.

Since immunohistochemistry is qualitative, highly purified DC populations were isolated from whole blood to assess the relative levels of PI-9. Consistent with the FACS data, low levels of PI-9 were present in monocytes purified from PBLs. IL-4- and GM-CSF-induced differentiation of these cells into immature MDDCs resulted in a significant increase in PI-9 expression (Fig. 7A). Maturation of MDDCs by exposure to TNF- resulted in a further increase in the expression of PI-9 (Fig. 7B). By densitometric analysis, this increase in PI-9 in MDDCs was 4-fold over monocytes and increased a further 3.5-fold upon maturation with TNF-.

View larger version (28K): [in this window] [in a new window]   FIGURE 7. Expression of PI-9 in primary DCs and MDDCs. A, Fifty micrograms of cell lysates were prepared from elutriated monocytes (Mono), sorted monocytes (sMono), lineage-negative DCs (lin- DC), monocyte-derived DCs (MDDC), and T cells; B, sorted monocytes were further divided into CD16+ and CD16- populations, lineage-negative DCs were divided into CD1b/c+ (Langerhans cell precursors) and CD123+ (plasmacytoid DCs), and MDDCs were cultured in the presence (+) or the absence (-) of TNF- (10 ng/ml) for 2 days. Samples were resolved by 12.5% reducing SDS-PAGE, transferred to nitrocellulose, and immunoblotted for PI-9 with 7D8 hybridoma supernatant diluted 1/10, detected with HRP conjugated anti-mouse Ig, and ECL. Blots were stripped and reprobed for actin (diluted 1/1000). C, Simplified diagram illustrating the differentiation of DCs from either a myeloid or a lymphoid precursor. Boxed populations were assessed for PI-9 by immunoblotting and immunohistochemistry (shades of gray represent relative levels of PI-9). Checkered boxes indicate that while PI-9-positive DCs were observed in the thymus, the phenotype of these DCs is not yet known. Dashed arrows indicate ex vivo stimulation. Data in this figure are modified from Ref. 94 with additional information from Refs. 46 48 81 , and 95 .

The differential expression of PI-9 in DC populations from both the myeloid and lymphoid lineages is illustrated in Fig. 7C. The distribution of PI-9 in DC subsets suggests that expression is not limited by ancestry, and that differing requirements for protection from grB during Ag presentation to naive CD8⁺ T cells during induction of effector functions determines PI-9 expression.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
Cells have evolved a number of mechanisms to control apoptosis. For example, inhibitor of apoptosis proteins inhibit caspases directly (49), cellular FLIP blocks Fas-mediated apoptosis (50), and Bcl-2 family members regulate apoptosis at the mitochondria (reviewed in Refs. 51 and 52). We and others believe that PI-9 and other intracellular serpins are part of the anti-apoptotic machinery of cells involved in or exposed to the cellular immune response (23, 41, 53, 54). In particular, we have proposed that PI-9 protects cells against misdirected grB (19, 21, 22, 24).

Expression, regulation, and function of PI-9 in CLs

A role for PI-9 in protecting grB-expressing cells is supported by its unusual intracellular distribution, described in the first part of this study. In addition to its cytoplasmic and nuclear localization (20), PI-9 in CLs is clearly associated with grB-containing cytotoxic granules. Fractionation studies indicate that PI-9 is not present within granules (19). Other studies show that, like PI-6 (55), when PI-9 is provided with an efficient signal peptide, it is retained in the endoplasmic reticulum and cannot move through the secretory pathway (A. Gillard and P. Bird, unpublished observations). Therefore, PI-9 must associate with the external, cytoplasmic face of the granule through interaction with a specific granule component. Our demonstration that PI-9 does not associate with lysosomes in epithelial cells suggests that it interacts with a protein or other component not found on nonsecretory lysosomes or on other membrane-bound organelles. For example, it may bind a specific lipid, as the lipid content of the granule membrane differs from that of the plasma membrane and other organelles (56).

GrB is stored in granules in an active form (57); thus, leakage from granules or from the synapse would allow it to access nucleocytoplasmic substrates and kill the CL. The positioning of PI-9 at the granule surface and of the PI-9/grB complexes evident within CLs suggests that granules do leak and that PI-9 is present to rapidly inactivate extragranular grB. Once granule exocytosis is triggered, the granules are refilled with newly synthesized grB; however, some of the newly synthesized grB is constitutively secreted as a 35-kDa form (45). The 35-kDa form of grB is specifically associated with degranulating cells, so the correlation we report with a 3-fold increase in PI-9 strongly suggests that grB misdirection occurs during T cell degranulation. While this in vitro system probably does not fully recapitulate the situation in vivo, our demonstration of an increase in CTL killing efficiency on 3- to 5-fold overexpression of PI-9 suggests that the similar fold up-regulation seen in Con A/PMA-treated cells is physiologically relevant. We therefore conclude that CTL viability is enhanced by a PI-9-mediated reduction in suicide or fratricide induced by misdirected grB.

What might cause granule leakage? Granules are secretory lysosomes containing lysosomal hydrolases in addition to granzymes and perforin (58, 59, 60). While there is no direct evidence that granules leak, it is clear that lysosomal rupture can be induced by stressors such as oxidation and UV irradiation, leading to apoptosis and necrosis (61, 62). Increased levels of reactive oxygen species have been observed in CLs, which may lead to apoptosis (63). This suggests that granule leakage occurs during effector cell activation and/or function.

Release of grB into the effector cell cytoplasm need not only occur from leaking granules. It is possible that secreted grB is endocytosed by effectors or bystanders. The uptake of grB into target cells is thought to be mediated by the 300-kDa M6PR (2). The M6PR is expressed in all nucleated cells, with up to 20% of the receptor present at the cell surface (64, 65, 66, 67, 68). Interestingly, the M6PR is up-regulated on activated T cells (69), which might increase their susceptibility to secreted grB.

Role of PI-9 in accessory cells

The cellular immune response involves a complex interplay between many cell types. APC or accessory cells (DCs, macrophages, and B cells) induce differentiation of naive T cells into cytotoxic or Th lymphocytes by secretion of cytokines and expression of costimulatory molecules. These accessory cells are closely associated with CLs and are likely to be exposed to collateral damage mediated by grB and perforin during the immune response. The presence of PI-9 would provide protection against inadvertent killing of these cells.

How likely is such inadvertent killing? DCs have established roles in presenting Ag to CD4⁺ Th cells and eliciting Th1 (CTL) or Th2 (B cell) responses. However, distinct DC subpopulations also directly interact with B cells or CD8⁺ CTLs. For example, follicular DCs in the germinal center directly contribute to B cell proliferation and differentiation (70), while virally infected DCs and DCs purified from blood can directly present to CD8⁺ T cells in the absence of CD4⁺ Th cells (71, 72, 73, 74).

This close association of activated CTLs and DCs may result in elimination of DCs by effector CTLs (33, 75). Elimination of DCs in normal mice is unusual, presumably due to protective mechanisms, but elimination of Ag-specific DCs by cognate CTLs has been observed in transgenic mouse models (76, 77). Although this demonstrates that DCs are potentially susceptible to CTLs, the mechanism of CTL-dependent clearance of DCs is unclear. One study found DC elimination to be independent of Fas and perforin (77), while another reports that it is mediated partly by the perforin pathway (78). Consistent with the latter results, we and others have suggested that expression of PI-9 in DCs prevents grB-mediated apoptosis during Ag presentation to CTLs (23, 53). This is further supported by the recent report that SPI6, one of seven murine PI-9 homologues (79), protects murine DCs from CTL-induced apoptosis (54).

Our results show that PI-9 is expressed in specific DC subsets. Thymic medullary DCs comprise three different subsets: a major CD11b^- subset of lymphoid origin, a minor CD11b⁺ subset of myeloid origin (46), and a population of plasmacytoid DCs (80). The CD11b⁺ thymic DCs resemble tonsillar germinal center DCs (81) and are thought to be phenotypically and morphologically related (46). Considering this relationship, it is likely that the PI-9-positive DCs observed in the thymus are related to the PI-9-positive DCs located in the tonsil. Both these DC populations are probably derived from CD16⁺ myeloid precursors (47, 48, 82). PI-9 is highly expressed in CD16⁺ monocytes, which is consistent with PI-9 expression in the CD11b⁺ thymic DCs and tonsillar germinal center DCs.

The differential expression of PI-9 in DCs suggests differing requirements for protection from grB-mediated apoptosis in DC subsets. Thymic medullary DCs are essential in the positive and negative selection of thymocytes. GrB-positive cells are present in the thymic medulla, with grB transcripts detected in double-positive (CD4⁺ CD8⁺) thymocytes (83) and in both CD4⁺ or CD8⁺ single-positive thymocytes (84). This suggests that thymocytes undergoing selection express grB and have cytotoxic potential. Thus, the presence of PI-9 in thymic medulla DCs is consistent with a role in protecting these DCs from grB-mediated apoptosis.

Some subsets of germinal center DCs are involved in the presentation and activation of T cells directly (81), while plasmacytoid DCs are IFN-producing cells (85, 86, 87) that initiate potent Th1 (CTL) responses (88). The expression of PI-9 in these cells suggests that DC populations that present to and activate CD8⁺ precursor T cells are at risk from the effector functions of the T cells they activate. This is also supported by the up-regulation of PI-9 in MDDCs upon TNF--induced maturation, suggesting that mature APC require protection from inadvertent apoptosis.

Role of PI-9 in other cells

It would be advantageous for other cell types to express PI-9 to protect against misdirected grB during the immune response. For example, PI-9 is expressed in endothelial and mesothelial cells likely to be exposed to CLs and is up-regulated by inflammatory stimuli (24, 89). The expression of grB and perforin has also been demonstrated in human CD4⁺ CTLs (90, 91), suggesting that PI-9 has a cytoprotective role in some CD4⁺ T cells. The level of PI-9 expressed in B cells, monocytes, and granulocytes is lower than in CLs or DCs, and it is unlikely that they would be protected from direct CTL attack. Hence, these cells have sufficient PI-9 to cope with low levels of misdirected grB, but could still be cleared by CTLs if they become infected or tumorigenic.

Two recent papers have indicated a role for PI-9 in tumor evasion by providing neoplastic cells with an advantage against grB-mediated cytotoxicity (92, 93). However, both studies failed to establish the baseline expression of PI-9 in tissues and cells or to compare the level of PI-9 expression in normal and tumor samples. The expression of PI-9 in epithelial cells has been reported (24), and PI-9 is in the ductal tissue of the breast, the columnar epithelia of the colon, and the ciliated columnar epithelia lining the female reproductive tract (M. Buzza, unpublished observations). The presence of PI-9 in carcinomas of breast, colon, and cervix (92) is therefore not surprising.

Additionally, the work reported here shows that PI-9 is widely distributed in normal leukocytes, which may account for the presence of PI-9 in T, B, and Hodgkin lymphomas (93). Analysis of the latter data indicates that only 28% of 224 biopsies were positive for PI-9. Furthermore, the number of PI-9-positive cells within each biopsy varied, with only 17% containing a majority of PI-9-positive tumor cells. The lack of PI-9 in most of these lymphomas suggests it is unlikely that PI-9 up-regulation is a common mechanism by which lymphomas resist immune destruction.

	Acknowledgments

 
We thank J. Sun for recombinant grB, J. Trapani (Peter MacCallum Cancer Institute, Melbourne, Australia) for grB Abs, A. Pshezhetsky (University of Montreal, Montreal, Canada) for cathepsin A Abs, P. Hosking (Department of Anatomical Pathology, Box Hill Hospital, Melbourne, Australia) for archival tissues, and R. Boyd and M. Malin (Department of Pathology and Immunology, Monash University, Clayton, Melbourne, Australia) for thymus tissue.

	Footnotes

 
¹ This work was supported by the National Health and Medical Research Council of Australia, and the National Institutes of Health (Grant AI45108). H.S.W. is funded by Senior Research Fellowship 148950.

² Address correspondence and reprint requests to Dr. Phillip Bird, Department of Biochemistry and Molecular Biology, Building 13B, Room G09, Monash University, Clayton 3800, Australia. E-mail address: phil.bird{at}med.monash.edu.au

³ Abbreviations used in this paper: grB, granzyme B; CL, cytotoxic lymphocyte; DC, dendritic cell; GFP, green fluorescence protein; MDDC, monocyte-derived DC; M6PR, mannose-6-phosphate receptor; NP40, Nonidet P-40; PI-9, proteinase inhibitor 9.

Received for publication April 19, 2002. Accepted for publication November 5, 2002.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Berke, G.. 1995. Unlocking the secrets of CTL and NK cells. Immunol. Today 16:343.[Medline]
2. Motyka, B., G. Korbutt, M. J. Pinkoski, J. A. Heibein, A. Caputo, M. Hobman, M. Barry, I. Shostak, T. Sawchuk, C. F. Holmes, et al 2000. Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell 103:491.[Medline]
3. Alimonti, J. B., L. Shi, P. K. Baijal, A. H. Greenberg. 2001. Granzyme B induces BID-mediated cytochrome c release and mitochondrial permeability transition. J. Biol. Chem. 276:6974.[Abstract/Free Full Text]
4. Barry, M., J. A. Heibein, M. J. Pinkoski, S. F. Lee, R. W. Moyer, D. R. Green, R. C. Bleackley. 2000. Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid. Mol. Cell. Biol. 20:3781.[Abstract/Free Full Text]
5. Heibein, J. A., I. S. Goping, M. Barry, M. J. Pinkoski, G. C. Shore, D. R. Green, R. C. Bleackley. 2000. Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members Bid and Bax. J. Exp. Med. 192:1391.[Abstract/Free Full Text]
6. Sutton, V. R., J. E. Davis, M. Cancilla, R. W. Johnstone, A. A. Ruefli, K. Sedelies, K. A. Browne, J. A. Trapani. 2000. Initiation of apoptosis by granzyme B requires direct cleavage of Bid, but not direct granzyme B-mediated caspase activation. J. Exp. Med. 192:1403.[Abstract/Free Full Text]
7. Andrade, F., S. Roy, D. Nicholson, N. Thornberry, A. Rosen, L. Casciola-Rosen. 1998. Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for CTL-induced apoptosis. Immunity 8:451.[Medline]
8. Yang, X., H. R. Stennicke, B. Wang, D. R. Green, R. U. Janicke, A. Srinivasan, P. Seth, G. S. Salvesen, C. J. Froelich. 1998. Granzyme B mimics apical caspases: description of a unified pathway for trans-activation of executioner caspase-3 and -7. J. Biol. Chem. 273:34278.[Abstract/Free Full Text]
9. Froelich, C. J., W. L. Hanna, G. G. Poirier, P. J. Duriez, D. D’Amours, G. S. Salvesen, E. S. Alnemri, W. C. Earnshaw, G. M. Shah. 1996. Granzyme B/perforin-mediated apoptosis of Jurkat cells results in cleavage of poly(ADP-ribose) polymerase to the 89-kDa apoptotic fragment and less abundant 64-kDa fragment. Biochem. Biophys. Res. Commun. 227:658.[Medline]
10. Thomas, D. A., C. Du, M. Xu, X. Wang, T. J. Ley. 2000. DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. Immunity 12:621.[Medline]
11. Sharif-Askari, E., A. Alam, E. Rheaume, P. J. Beresford, C. Scotto, K. Sharma, D. Lee, W. E. DeWolf, M. E. Nuttall, J. Lieberman, et al 2001. Direct cleavage of the human DNA fragmentation factor-45 by granzyme B induces caspase-activated DNase release and DNA fragmentation. EMBO J. 20:3101.[Medline]
12. Stinchcombe, J. C., G. M. Griffiths. 2001. Normal and abnormal secretion by haemopoietic cells. Immunology 103:10.[Medline]
13. Spaeny-Dekking, E. H., W. L. Hanna, A. M. Wolbink, P. C. Wever, A. J. Kummer, A. J. Swaak, J. M. Middeldorp, H. G. Huisman, C. J. Froelich, C. E. Hack. 1998. Extracellular granzymes A and B in humans: detection of native species during CTL responses in vitro and in vivo. J. Immunol. 160:3610.[Abstract/Free Full Text]
14. Lauw, F. N., A. J. Simpson, C. E. Hack, J. M. Prins, A. M. Wolbink, S. J. van Deventer, W. Chaowagul, N. J. White, T. van Der Poll. 2000. Soluble granzymes are released during human endotoxemia and in patients with severe infection due to Gram-negative bacteria. J. Infect. Dis. 182:206.[Medline]
15. Berthou, C., J. P. Marolleau, C. Lafaurie, A. Soulie, L. Dal Cortivo, J. F. Bourge, M. Benbunan, M. Sasportes. 1995. Granzyme B and perforin lytic proteins are expressed in CD34⁺ peripheral blood progenitor cells mobilized by chemotherapy and granulocyte colony-stimulating factor. Blood 86:3500.[Abstract/Free Full Text]
16. Froelich, C. J., X. Zhang, J. Turbov, D. Hudig, U. Winkler, W. L. Hanna. 1993. Human granzyme B degrades aggrecan proteoglycan in matrix synthesized by chondrocytes. J. Immunol. 151:7161.[Abstract]
17. Ronday, H. K., W. H. van der Laan, P. P. Tak, J. A. de Roos, R. A. Bank, J. M. TeKoppele, C. J. Froelich, C. E. Hack, P. C. Hogendoorn, F. C. Breedveld, et al 2001. Human granzyme B mediates cartilage proteoglycan degradation and is expressed at the invasive front of the synovium in rheumatoid arthritis. Rheumatology 40:55.[Abstract/Free Full Text]
18. Gahring, L., N. G. Carlson, E. L. Meyer, S. W. Rogers. 2001. Granzyme B proteolysis of a neuronal glutamate receptor generates an autoantigen and is modulated by glycosylation. J. Immunol. 166:1433.[Abstract/Free Full Text]
19. Sun, J., C. H. Bird, V. Sutton, L. McDonald, P. B. Coughlin, T. A. De Jong, J. A. Trapani, P. I. Bird. 1996. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J. Biol. Chem. 271:27802.[Abstract/Free Full Text]
20. Bird, C. H., E. J. Blink, C. E. Hirst, M. S. Buzza, P. M. Steele, J. Sun, D. A. Jans, P. I. Bird. 2001. Nucleocytoplasmic distribution of the ovalbumin serpin PI-9 requires a nonconventional nuclear import pathway and the export factor Crm1. Mol. Cell. Biol. 21:5396.[Abstract/Free Full Text]
21. Bird, C. H., V. R. Sutton, J. Sun, C. E. Hirst, A. Novak, S. Kumar, J. A. Trapani, P. I. Bird. 1998. Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol. Cell. Biol. 18:6387.[Abstract/Free Full Text]
22. Hirst, C. E., M. S. Buzza, V. R. Sutton, J. A. Trapani, K. L. Loveland, P. I. Bird. 2001. Perforin-independent expression of granzyme B and proteinase inhibitor 9 in human testis and placenta suggests a role for granzyme B-mediated proteolysis in reproduction. Mol. Hum. Reprod. 7:1133.[Abstract/Free Full Text]
23. Bladergroen, B. A., M. C. Strik, N. Bovenschen, O. van Berkum, G. L. Scheffer, C. J. Meijer, C. E. Hack, J. A. Kummer. 2001. The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites. J. Immunol. 166:3218.[Abstract/Free Full Text]
24. Buzza, M. S., C. E. Hirst, C. H. Bird, P. Hosking, J. McKendrick, P. I. Bird. 2001. The granzyme B inhibitor, PI-9, is present in endothelial and mesothelial cells, suggesting that it protects bystander cells during immune responses. Cell. Immunol. 210:21.[Medline]
25. Scott, F. L., J. E. Paddle-Ledinek, L. Cerruti, P. B. Coughlin, H. H. Salem, P. I. Bird. 1998. Proteinase inhibitor 6 (PI-6) expression in human skin: induction of PI-6 and a PI-6/proteinase complex during keratinocyte differentiation. Exp. Cell. Res. 245:263.[Medline]
26. Apostolidis, V. A., K. A. Browne, M. J. Smyth, J. A. Trapani. 1995. The peptide loop consisting of amino acids 139–157 of human granzyme B (fragmentin 2) contains an immunodominant epitope recognized by the mouse. Mol. Immunol. 32:909.[Medline]
27. Edwards, K. M., C. M. Kam, J. C. Powers, J. A. Trapani. 1999. The human cytotoxic T cell granule serine protease granzyme H has chymotrypsin-like (chymase) activity and is taken up into cytoplasmic vesicles reminiscent of granzyme B-containing endosomes. J. Biol. Chem. 274:30468.[Abstract/Free Full Text]
28. Zhang, X., R. Ren. 1998. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 92:3829.[Abstract/Free Full Text]
29. Burns, J. C., T. Friedmann, W. Driever, M. Burrascano, J. K. Yee. 1993. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA 90:8033.[Abstract/Free Full Text]
30. Medhurst, A. D., D. C. Harrison, S. J. Read, C. A. Campbell, M. J. Robbins, M. N. Pangalos. 2000. The use of TaqMan RT-PCR assays for semiquantitative analysis of gene expression in CNS tissues and disease models. J. Neurosci. Methods 98:9.[Medline]
31. Leo, O., M. Foo, D. H. Sachs, L. E. Samelson, J. A. Bluestone. 1987. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl. Acad. Sci. USA 84:1374.[Abstract/Free Full Text]
32. Wano, Y., T. Uchiyama, K. Fukui, H. Uchino, J. Yodoi. 1984. Characterization of human interleukin 2 receptor (Tac antigen) in normal and leukemic T cells: co-expression of normal and aberrant receptors on Hut-102 cells. J. Immunol. 132:3005.[Abstract]
33. Liu, C. C., S. Rafii, A. Granelli-Piperno, J. A. Trapani, J. D. Young. 1989. Perforin and serine esterase gene expression in stimulated human T cells: kinetics, mitogen requirements, and effects of cyclosporin A. J. Exp. Med. 170:2105.[Abstract/Free Full Text]
34. Warren, H. S., L. J. Skipsey. 1991. Phenotypic analysis of a resting subpopulation of human peripheral blood NK cells: the FcRIII (CD16) molecule and NK cell differentiation. Immunology 72:150.[Medline]
35. Warren, H. S., B. F. Kinnear. 1999. Quantitative analysis of the effect of CD16 ligation on human NK cell proliferation. J. Immunol. 162:735.[Abstract/Free Full Text]
36. Sun, J., C. H. Bird, M. S. Buzza, K. E. McKee, J. C. Whisstock, P. I. Bird. 1999. Expression and purification of recombinant human granzyme B from Pichia pastoris. Biochim. Biophys. Acta 261:251.
37. Zapata, J. M., R. Takahashi, G. S. Salvesen, J. C. Reed. 1998. Granzyme release and caspase activation in activated human T-lymphocytes. J. Biol. Chem. 273:6916.[Abstract/Free Full Text]
38. Ito, T., M. Inaba, K. Inaba, J. Toki, S. Sogo, T. Iguchi, Y. Adachi, K. Yamaguchi, R. Amakawa, J. Valladeau, et al 1999. A CD1a⁺/CD11c⁺ subset of human blood dendritic cells is a direct precursor of Langerhans cells. J. Immunol. 163:1409.[Abstract/Free Full Text]
39. Olweus, J., A. BitMansour, R. Warnke, P. A. Thompson, J. Carballido, L. J. Picker, F. Lund-Johansen. 1997. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc. Natl. Acad. Sci. USA 94:12551.[Abstract/Free Full Text]
40. Romani, N., S. Gruner, D. Brang, E. Kampgen, A. Lenz, B. Trockenbacher, G. Konwalinka, P. O. Fritsch, R. M. Steinman, G. Schuler. 1994. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180:83.[Abstract/Free Full Text]
41. Scott, F. L., C. E. Hirst, J. Sun, C. H. Bird, S. P. Bottomley, P. I. Bird. 1999. The intracellular serpin proteinase inhibitor 6 is expressed in monocytes and granulocytes and is a potent inhibitor of the azurophilic granule protease, cathepsin G. Blood 93:2089.[Abstract/Free Full Text]
42. Stavridi, E. S., K. O’Malley, C. M. Lukacs, W. T. Moore, J. D. Lambris, D. W. Christianson, H. Rubin, B. S. Cooperman. 1996. Structural change in -chymotrypsin induced by complexation with 1-antichymotrypsin as seen by enhanced sensitivity to proteolysis. Biochemistry 35:10608.[Medline]
43. Huntington, J. A., R. J. Read, R. W. Carrell. 2000. Structure of a serpin-protease complex shows inhibition by deformation. Nature 407:923.[Medline]
44. Zang, X., R. Ren. 1998. Bcr-Abl effeciently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimultating factor in mice: a novel model of chronic myelogenous leukemia. Blood 92:3829.
45. Isaaz, S., K. Baetz, K. Olsen, E. Podack, G. M. Griffiths. 1995. Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re-filling of the lytic granules and secretion of lytic proteins via a non-granule pathway. Eur. J. Immunol. 25:1071.[Medline]
46. Vandenabeele, S., H. Hochrein, N. Mavaddat, K. Winkel, K. Shortman. 2001. Human thymus contains 2 distinct dendritic cell populations. Blood 97:1733.[Abstract/Free Full Text]
47. Grage-Griebenow, E., R. Zawatzky, H. Kahlert, L. Brade, H. Flad, M. Ernst. 2001. Identification of a novel dendritic cell-like subset of CD64⁺/CD16⁺ blood monocytes. Eur. J. Immunol. 31:48.[Medline]
48. Sanchez-Torres, C., G. S. Garcia-Romo, M. A. Cornejo-Cortes, A. Rivas-Carvalho, G. Sanchez-Schmitz. 2001. CD16⁺and CD16^- human blood monocyte subsets differentiate in vitro to dendritic cells with different abilities to stimulate CD4⁺ T cells. Int. Immunol. 13:1571.[Abstract/Free Full Text]
49. Deveraux, Q. L., R. Takahashi, G. S. Salvesen, J. C. Reed. 1997. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388:300.[Medline]
50. Kataoka, T., M. Schroter, M. Hahne, P. Schneider, M. Irmler, M. Thome, C. J. Froelich, J. Tschopp. 1998. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and irradiation. J. Immunol. 161:3936.[Abstract/Free Full Text]
51. Adams, J. M., S. Cory. 2001. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem. Sci. 26:61.[Medline]
52. Shi, Y.. 2001. A structural view of mitochondria-mediated apoptosis. Nat. Struct. Biol. 8:394.[Medline]
53. Bird, P. I.. 1999. Regulation of pro-apoptotic leucocyte granule serine proteinases by intracellular serpins. Immunol. Cell. Biol. 77:47.[Medline]
54. Medema, J. P., D. H. Schuurhuis, D. Rea, J. van Tongeren, J. de Jong, S. A. Bres, S. Laban, R. E. Toes, M. Toebes, T. N. Schumacher, et al 2001. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J. Exp. Med. 194:657.[Abstract/Free Full Text]
55. Scott, F. L., P. B. Coughlin, C. Bird, L. Cerruti, J. A. Hayman, P. Bird. 1996. Proteinase inhibitor 6 cannot be secreted, which suggests it is a new type of cellular serpin. J. Biol. Chem. 271:1605.[Abstract/Free Full Text]
56. Takai, Y., T. Masuko, H. Takeuchi. 1997. Lipid structure of cytotoxic granules in living human killer T lymphocytes studied by Raman microspectroscopy. Biochim. Biophys. Acta 1335:199.[Medline]
57. Pham, C. T., T. J. Ley. 1999. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc. Natl. Acad. Sci. USA 96:8627.[Abstract/Free Full Text]
58. Peters, P. J., J. Borst, V. Oorschot, M. Fukuda, O. Krahenbuhl, J. Tschopp, J. W. Slot, H. J. Geuze. 1991. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J. Exp. Med. 173:1099.[Abstract/Free Full Text]
59. Burkhardt, J. K., S. Hester, C. K. Lapham, Y. Argon. 1990. The lytic granules of natural killer cells are dual-function organelles combining secretory and pre-lysosomal compartments. J. Cell Biol. 111:2327.[Abstract/Free Full Text]
60. Page, L. J., A. J. Darmon, R. Uellner, G. M. Griffiths. 1998. L is for lytic granules: lysosomes that kill. Biochim. Biophys. Acta 1401:146.[Medline]
61. Brunk, U. T., H. Dalen, K. Roberg, H. B. Hellquist. 1997. Photo-oxidative disruption of lysosomal membranes causes apoptosis of cultured human fibroblasts. Free Radical Biol. Med. 23:616.[Medline]
62. Brunk, U. T., J. Neuzil, J. W. Eaton. 2001. Lysosomal involvement in apoptosis. Redox. Rep. 6:91.[Medline]
63. Hildeman, D. A., T. Mitchell, T. K. Teague, P. Henson, B. J. Day, J. Kappler, P. C. Marrack. 1999. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity 10:735.[Medline]
64. Willingham, M. C., I. H. Pastan, G. G. Sahagian. 1983. Ultrastructural immunocytochemical localization of the phosphomannosyl receptor in Chinese hamster ovary (CHO) cells. J. Histochem. Cytochem. 31:1.[Abstract]
65. Geuze, H. J., J. W. Slot, G. J. Strous, A. Hasilik, K. Von Figura. 1984. Ultrastructural localization of the mannose 6-phosphate receptor in rat liver. J. Cell Biol. 98:2047.[Abstract/Free Full Text]
66. Geuze, H. J., J. W. Slot, G. J. Strous, A. Hasilik, K. von Figura. 1985. Possible pathways for lysosomal enzyme delivery. J. Cell Biol. 101:2253.[Abstract/Free Full Text]
67. Braulke, T., C. Gartung, A. Hasilik, K. von Figura. 1987. Is movement of mannose 6-phosphate-specific receptor triggered by binding of lysosomal enzymes?. J. Cell Biol. 104:1735.[Abstract/Free Full Text]
68. Griffiths, G., R. Matteoni, R. Back, B. Hoflack. 1990. Characterization of the cation-independent mannose 6-phosphate receptor-enriched prelysosomal compartment in NRK cells. J. Cell Sci. 95:441.[Abstract/Free Full Text]
69. Hindmarsh, E. J., M. A. Staykova, D. O. Willenborg, C. R. Parish. 2001. Cell surface expression of the 300 kDa mannose-6-phosphate receptor by activated T lymphocytes. Immunol. Cell. Biol. 79:436.[Medline]
70. Grouard, G., O. de Bouteiller, J. Banchereau, Y. J. Liu. 1995. Human follicular dendritic cells enhance cytokine-dependent growth and differentiation of CD40-activated B cells. J. Immunol. 155:3345.[Abstract]
71. Bhardwaj, N., A. Bender, N. Gonzalez, L. K. Bui, M. C. Garrett, R. M. Steinman. 1994. Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8⁺ T cells. J. Clin. Invest. 94:797.
72. Young, J. W., R. M. Steinman. 1990. Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4⁺ helper T cells. J. Exp. Med. 171:1315.[Abstract/Free Full Text]
73. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478.[Medline]
74. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480.[Medline]
75. Oehen, S., K. Brduscha-Riem. 1998. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J. Immunol. 161:5338.[Abstract/Free Full Text]
76. Hermans, I. F., D. S. Ritchie, J. Yang, J. M. Roberts, F. Ronchese. 2000. CD8⁺ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J. Immunol. 164:3095.<